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1 |  INTRODUCTION
The constant emergence of new treatment modalities for ten-
dinopathy over the last few decades and the absence of ro-
bust evidence for their effectiveness has led to an increasing 
number of randomized controlled trials (RCTs). Systematic 
reviews (SRs) of RCTs constitute the strongest level of ev-
idence and can therefore inform clinical practice, both at a 
policy level and an individual physician level. A SR should 
be transparent and reproducible, and subjectivity should be 
kept to a minimum.1 Unfortunately, firm guidance on con-
ducting a SR does not exist and several parameters are left to 
the judgment of the authors. Moreover, recent debate in the 
Lancet argues that the findings of SRs may be flawed as they 
often include poor-quality studies that should have not been 
published in the first place.2
One of these parameters is risk of bias (RoB) assessment; 
not only is it a subjective process in its nature, but the exis-
tence of several RoB assessment tools further decreases re-
producibility by introducing inconsistency. RoB assessment 
plays an integral role in SRs, and it is an essential part of 
data synthesis and the reporting of the results. It can be used 
in one of two ways in a SR, either for subgroup analyses (ie, 
including only RCTs with low risk of bias) or in determining 
the strength of evidence for each result in conjunction with 
other limitations of the included evidence that arise as a result 
of combining the findings of different studies (consistency, 
imprecision, etc).3
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We aimed to provide an overview of the use of risk of bias (RoB) assessment tools 
in systematic reviews (SRs) in tendinopathy management given increased scrutiny 
of the SR literature in clinical decision making. A search was conducted in Medline 
from inception to June 2020 for all SRs of randomized controlled trials (RCTs) as-
sessing the effectiveness of any intervention(s) on any location(s) of tendinopathy. 
Included SRs had to use one of (a) Cochrane Collaboration tool, (b) PEDro scale, or 
(c) revised Cochrane Collaboration tool (RoB 2) for their RoB assessment. A total 
of 46 SRs were included. Around half of SRs (46%) did not use an RoB assessment 
in data synthesis, and only 30% used it to grade the certainty of evidence. The RoB 
2 tool was the most likely to determine “overall high RoB” (52%) followed by the 
Cochrane Collaboration tool (34.6%) and the PEDro scale (18.6%) as determined by 
the authors of the SRs. We have demonstrated substantial problems associated with 
the use of RoB assessments in tendinopathy SRs. The universal use of a single RoB 
assessment tool should be promoted by journals and SR guidance documents.
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The Cochrane Collaboration tool4 for assessing internal 
validity (RoB), which was introduced in 2008 and is the 
tool most frequently used in SRs of RCTs, consists of 7 
components/questions, which can be rated as “low” risk, 
“unclear” risk, or “high” risk of bias. Through its use over 
the last decade, it has been associated with a lot of confu-
sion, low inter-rater reliability, and wrong implementation 
in SRs.5 Additionally, the creators did not specify how the 
tool should be used to determine overall RoB for each as-
sessed RCT and instead they advised an overall judgment of 
the result at a domain and not study level, which is both im-
practical and very subjective. The second most commonly 
used tool, the PEDro scale,6,7 is a scoring system that can 
be used to determine overall RoB for each study based on 
the overall score out of 10. It includes all the domains of 
the Cochrane tool and some additional items, and unlike 
the Cochrane tool, it is less subjective as the assessor only 
has two possible answers for each item/question: “yes” or 
“no.” The main disadvantage of its simplicity, however, is 
that methodological aspects of the assessed RCT that are 
not described clearly in the article are automatically scored 
with a “no,” whereas the Cochrane tool has an “unclear” 
option, which again is not clear how it should be used in the 
determination of the overall RoB.
The Cochrane group has recently published a revised RoB 
assessment tool, the RoB 2,5 which, according to the authors, 
is less subjective, more reproducible, and has more direct 
implementations in data synthesis. It is made up of 5 items/
questions, and each one has a number of signaling questions, 
which help the author reach a final conclusion about the 
RoB in each item according to a pre-defined formula. This 
can either be “low” risk, “high” risk, or “some concerns.” 
The creators, having realized the importance of determining 
overall RoB for each study for practical and reproducible im-
plementation of the RoB assessment in data synthesis, have 
also described how decisions on overall RoB for each study 
should be reached. Finally, they highlight that RoB should be 
assessed on an outcome level for each included RCT.5
The introduction of the new RoB assessment tool, regard-
less of whether it is more effective or not than other tools 
at predicting the actual RoB, is expected to further increase 
inconsistency across different SRs. This has the potential to 
lead to conflicting conclusions between SRs assessing and 
comparing the same interventions with regard to the strength 
of evidence of the results and can cause confusion in the 
translation of the findings and their implementation in clini-
cal practice.
The aims of the present were (a) to provide an overview of 
the use of RoB assessment tools in SRs of RCTs in tendinop-
athy through a scoping review and (b) to assess inter-tool re-
liability among the Cochrane Collaboration tool, the revised 
Cochrane Collaboration tool (RoB 2), and the PEDro scale 
at determining overall RoB in tendinopathy SRs. Finally, 
we provide recommendations at an RCT level, SR level, and 
journal level with an ultimate objective to make RoB assess-
ment and its use in data syntheses as understandable, trans-
parent, objective, and reproducible as possible.
2 |  METHODS
2.1 | Eligibility
SRs were eligible if they assessed the effectiveness of any 
intervention(s) on any location(s) of tendinopathy in patients 
over 16 years of age, included only RCTs, and used one of 
the following RoB assessment tools: Cochrane Collaboration 
tool, PEDro scale, RoB 2 tool (revised Cochrane Collaboration 
tool). Exclusion criteria included SRs including a mixture of 
randomized and non-randomized studies and a mixture of 
participants with tendinopathy and other conditions. SRs in 
languages other than English were also excluded. No crite-
ria were used regarding the following parameters: publica-
tion date, journal type, type of tendinopathy and intervention, 
outcome measures, and length of follow-up.
2.2 | Search strategy—Screening
A literature search was conducted by the first author via 
Medline in June 2020 with the following Boolean operators 
in “All Fields”: “((systematic review) OR (meta-analysis) 
AND (tendin*) AND (randomi*)).
For all eligible articles, the reference lists and PubMed's 
“similar articles” list were screened to identify potentially el-
igible articles that may have been missed at the initial search. 
Figure 1 (PRISMA flowchart) illustrates the article screening 
process.
The initial search returned a total of 208 articles. After ex-
clusion of non-eligible articles according to our pre-defined 
criteria and inclusion of articles identified from reference 
screening, 46 SRs were included in our review.
2.3 | Data Extraction—Handling
2.3.1 | Scoping review
The included SRs were read by the first author, and data were 
extracted in a Microsoft Word table regarding the following: 
(a) general SR characteristics (number of included RCTs, 
location(s) of tendinopathy, intervention(s) assessed, key 
findings), (b) RoB assessment tool used, (c) whether an over-
all RoB was determined for each assessed RCT, (d) whether 
RoB assessment was performed on a study or outcome level, 
and (e) how RoB assessment was used in data syntheses.
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2.3.2 | Assessment of consistency of risk of 
bias assessment
In order to assess for disparity of tools determining overall 
RoB, we used two separate methods. Firstly, we calculated 
the proportion of RCTs assessed in all included SRs being 
determined as of “high overall RoB” for each one of the 3 
tools separately and the mean proportion for each tool. Where 
overall RoB was determined by the authors of the original SR 
for each RCT, this was used. We also used our own pre-de-
fined criteria (see below) to determine overall RoB for each 
RCT based on the RoB assessment results reported by the 
SR authors. Inter-tool reliability was not evaluated formally 
with statistical tests for this method as the RCTs assessed 
by each tool were not the same; instead, our purpose was to 
give a general impression on the likelihood of each tool to 
determine “high overall RoB” for RCTs and investigate for 
inter-rater inconsistencies when different criteria are used for 
the same studies.
Secondly, in light of the newly published RoB 2 tool by the 
Cochrane Collaboration and its use by the most recently pub-
lished SR of RCTs in Achilles tendinopathy by van der Vlist 
et al,8 we assessed RoB of its 29 included RCTs using the two 
other RoB assessment tools, the Cochrane Collaboration tool 
and the PEDro scale. We then compared the reliability among 
the three tools (Cochrane Collaboration and PEDro as per-
formed by the authors of the present review and RoB 2 by the 
authors of the original SR) at determining overall RoB. We 
only tested inter-tool reliability for overall RoB determination 
and not specific domains of the tools as only the former is 
directly associated with implementation of RoB assessment 
in data synthesis.
Inter-tool reliability was only assessed for determining 
“high overall RoB,” which is the aspect of RoB assessment 
with direct application in data syntheses. “High overall 
RoB” RCTs determine downgrading of the quality of the 
evidence, and they are the studies removed for subgroup/
sensitivity analyses. For the purposes of the statistical tests, 
the 29 assessed RCTs were divided in two categories, “high 
overall RoB” and “other” (“low overall RoB”/”unclear 
RoB”/”some concerns”), and each category represented 
each one of the two possible outcomes in the Cohen's kappa 
formulas.
Overall RoB determination (our criteria)
The RoB 2 tool provides clear, specific instructions on how 
the overall RoB for each study should be determined5; there-
fore, we only used the SR authors' assessment.
With regard to the PEDro scale, its final score is tradi-
tionally interpreted as 8-10 “excellent quality” and 6-7 “good 
quality”; therefore, we used ≥6 as a cutoff to divide high 
and low overall RoB (or low and high study quality, respec-
tively) firstly as this is the criterion most commonly used 
by SR authors (PEDro ≥ 6). We also used ≥8 as a cutoff to 
F I G U R E  1  PRISMA flow 
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see which score gives more similar results to the other tools 
(PEDro ≥ 8). As the majority of authors use the PEDro scale 
for “study quality” and not RoB assessment, for the purposes 
of this review “high overall RoB” was synonymous to “mod-
erate” or “poor” study quality.
For the Cochrane Collaboration tool, RCTs were considered 
as “high overall RoB” if they had: (a) high RoB in any of “ran-
dom sequence generation,” “allocation concealment,” “blinding 
of patients and staff,” or “blinding of outcome measures” or (b) 
high RoB in 2 or more of the remaining 3 items (“complete-
ness of outcome data,” “selective reporting,” and “other”) or 
(c) high RoB in one of the 3 remaining domains if the authors 
felt the RoB introduced through that domain was significant 
enough to affect the results of the study. “Unclear overall RoB” 
was assigned to studies with 3 or more unclear RoB in individ-
ual domains not fulfilling the criteria for “high overall RoB,” 
and “low overall RoB” in those not fulfilling the criteria for 
high and unclear overall RoB. These criteria, especially for the 
Cochrane tool and to a lesser extent for the PEDro scale, have 
been specified by the authors of the present review based on 
advice deriving from the creators of the Cochrane tool and other 
researchers9-11; they do not represent the “appropriate” criteria 
as the creators themselves did not specify any; however, we use 
them to emphasize the extent of inconsistency and subjectivity.
2.4 | Statistical analysis
Cohen's kappa statistic was used to assess inter-tool reli-
ability at determining “high overall RoB.” According to the 
value of the statistic (range 0-1), the strength of agreement 
can be: equivalent to chance (0), slight (0.1-0.2), fair (0.21-
0.4), moderate (0.41-0.6), substantial (0.61-0.8), near perfect 
(0.81-0.99), perfect (1).
The following formula was used for the calculation of 
Cohen's statistic between each combination of two tools:
where Po: the sum of the mutual RCTs rated as “high over-
all RoB” and “other” in the two tools; Pe: (proportion of “high 
overall RoB” RCTs multiplied by proportion of “other” RCTs 
in tool 1) + (proportion of “high overall RoB” RCTs multiplied 
by proportion of “other” RCTs in tool 2).
3 |  RESULTS
3.1 | Scoping review
Table  1 summarizes the key characteristics of the eli-
gible SRs.8,12-56 Of the 46 included SRs, 31 used the 
Cochrane Collaboration tool, 13 the PEDro scale, 2 the 
revised Cochrane Collaboration tool (RoB 2), and 2 both 
the Cochrane Collaboration tool and the PEDro scale. 
Modified versions of the PEDro scale and the Cochrane 
Collaboration tool were used by two and one SRs, respec-
tively. RoB was assessed on an outcome and not study 
level in only 3 SRs (6.5%). An overall RoB for each as-
sessed RCT/outcome was determined in 17 SRs (37%; 
n  =  7 PEDro scale, n  =  2 RoB 2 tool, n  =  8 Cochrane 
Collaboration tool). A total of 21 SRs (46%) did not use the 
results of their RoB assessment anywhere in data synthe-
sis; the remaining 25 that did used it for either subgroup/
sensitivity analyses excluding “high overall RoB”/”low-
quality” studies (n  =  9; 36%), for grading the quality of 
the evidence (n = 14; 56%), or both (n = 1; 4%). Where 
the quality of the evidence was graded, tools used included 
the GRADE tool3 (n = 6; 43%), the Cochrane BRG tool9 
(n = 5; 36%), and the NHMRC tool1 (n = 1; 7%), while 
the authors of 3 SRs (21%) graded the evidence arbitrarily 
without a pre-specified method.
3.1.1 | Overall RoB determination
Where authors of SRs determined overall RoB of assessed 
RCTs, the following methods were used for each tool:
• RoB 2: according to the instructions of the tool (n = 2)
• Cochrane Collaboration tool: (a) “overall high RoB” where 
<3 domains had low RoB (n = 2) or where >3 domains had 
high RoB (n = 1); (b) “overall low RoB” where the total 
score of the study was >70% (out of 16; low RoB scored 2, 
unclear RoB 1, and high RoB 0, n = 1); (c) “good quality 
study” where no more than 1 domains of the tool, precision 
and external validity were high RoB (n = 2); (d) method 
not described (n = 2)
• PEDro: (a) “overall good quality/low RoB” where total 
score ≥6/10 (n = 4), ≥7/10 (n = 1 lee) or ≥7/13 for mod-
ified PEDro (n = 1); (b) “overall low quality/high RoB” 
where total score < 5/10 (n = 2)
3.2 | Assessment of consistency of risk of 
bias assessment
Table 2 shows the proportion of “overall high RoB” RCTs 
as determined by (a) the authors of the original SRs where 
performed, using their own “high overall RoB” criteria and 
(b) the first author of the present review (DC) based on the 
RoB assessment performed by the SR authors using our pre-
defined “high overall RoB” criteria for each tool. Mean per-
centages were calculated for each tool.
k= (Po−Pe)∕(1−Pe)
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3.2.1 | Consistency among tools
Based on the overall RoB assessments reported by the au-
thors of the original SRs, the RoB 2 tool was the most likely 
to determine a “high overall RoB” (mean proportion of high 
RoB RCTs 52%), followed by the Cochrane Collaboration 
tool (mean proportion 34.6%). The PEDro scale was associ-
ated with the lowest mean proportion of “high overall RoB” 
RCTs (18.6%).
When the pre-defined criteria of the authors of the pres-
ent review were applied, the PEDro ≥ 8 was associated with 
the highest proportion of high RoB studies (65.4%), followed 
by the Cochrane Collaboration tool (55%), and finally the 
PEDro ≥ 6 (29.2%).
3.2.2 | Consistency when different criteria 
used (SR authors vs authors of present review)
Where we determined “high overall RoB” using our crite-
ria based on the RoB assessment results of the SR authors, 
the mean proportion of “high overall RoB” studies was 
substantially higher compared to that of the SR authors 
for the Cochrane Collaboration tool (55% vs 34.6%) and 
for the PEDro ≥ 8 (65.4% vs 18.6%). For the PEDro ≥ 6, 
the difference was less significant (29.2% vs 18.2%) as the 
majority of SR authors using the PEDro chose a ≥6 cutoff 
too. The highest variability for individual SRs between the 
proportion of studies with “high overall RoB” of the SR 
authors and ours was observed in the Cochrane tool (eg, 
3% vs 73% for Dong et al29; 0% vs 72% for Fitzpatrick 
et al31) and the PEDro ≥ 8 (eg, 0% vs 82% for Haslerud 
et al32).
3.2.3 | Inter-tool reliability in example 
systematic review
Tables  3a and 3b shows the RoB assessment that we per-
formed for the 29 RCTs of the van der Vlist7 SR using the 
Cochrane Collaboration tool (Table 3a) and PEDro scale (≥6 
and ≥ 8) (Table 3b) with our criteria. Table 3c shows the RoB 
assessment as performed by van der Vlist et al7 using the RoB 
2 tool and the results of the overall RoB assessment from the 
other two tools as derived from Tables 3a and 3b, highlight-
ing the generally poor inter-tool reliability. The only compar-
ison that produced substantial reliability (k = 0.76) was that 
between the Cochrane tool and the PEDro ≥ 8. Fair reliability 
was found for the comparisons between the Cochrane tool 
and the PEDro ≥ 6 (k = 0.36), the Cochrane and the RoB 2 
(k = 0.29), and the RoB 2 and PEDro ≥ 8 (k = 0.26). Finally, 
inter-tool reliability between the RoB 2 and the PEDro ≥ 6 
was only slight (k = 0.03).A
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T A B L E  2  Determination of high overall RoB with the 3 tools using the systematic review authors' criteria and our criteria
Tool SR
SR authors' “high 
overall RoB”
DC “high overall 
RoB” Cochrane 
Collaboration DC “high overall RoB” PEDro
PEDro ≥6/10 ≥8/10
Bjordal et al (2008) 1/18 (6%) - NA NA
Chen et al (2019) ND - 2/11 (18%) 4/11 (36%)
Coombes et al (2010) 23/64 (36%) - 29/64 (45%) 46/64 (72%)
de Vos et al (2014) 2/6 (33%) - 2/6 (33%)* 4/6 (66%)
Haslerud et al (2015) 0/17 (0%) - 3/17 (18%) 14/17 (82%)
Ioppolo et al (2013) ND - NA NA
Lee et al (2011) 3/9 (33%) - 3/9 (33%)* 6/9 (66%)
Liao et al (2018) 0/29 (0%) - 0/29 (0%)* 13/29 (45%)
Mendonca et al (2020) 2/9 (22%) - 3/9 (33%) 5/9 (56%)
Ortega-Castillo & Medina-
Porqueres (2016)
ND - 2/12 (17%) 10/12 (83%)
Wasielewski & Kotsko (2007) ND - 5/11 (45%) 9/11 (82%)
Wu et al (2017) ND - NA NA
Mean Proportion 18.6% - 29.2% 65.4%
Cochrane Collaboration Arirachakaran et al (2016) ND 7/10 (70%) - -
Arirachakaran et al (2017) ND 3/7 (43%) - -
Bannuru et al (2014) ND NA - -
Boudreault et al (2014) ND 7/12 (58%) - -
Catapano et al (2020) ND 3/6 (50%) - -
Challoumas et al (2019a) ND 9/12 (75%) - -
Challoumas et al (2019b) ND 6/10 (60%) - -
Dan et al (2019) ND 2/2 (100%) - -
Desjardins-Charbonneau 
et al (2015a)
ND 10/10 (100%) - -
Desjardins-Charbonneau 
et al (2015b)
16/21 (76%) 20/21 (95%) - -
Desmeules et al (2016a) 8/10 (80%) 10/10 (100%) - -
Desmeules et al (2016b) ND 6/6 (100%) - -
Desmeules et al (2015) ND 9/11 (82%) - -
Dong et al (2015) 1/33 (3%) 24/33 (73%) - -
Dong et al (2016) 1/27 (4%) 10/27 (37%) - -
Fitzpatrick et al (2017) 0/18 (0%) 13/18 (72%) - -
Lafrance et al (2019) 2/3 (66%) 2/3 (66%) - -
Li et al (2019) ND 4/7 (57%) - -
Lin et al (2020) ND 2/5 (40%) - -
Lin et al (2019) 0/7 (0%) NA - -
Lin et al (2018) 0/6 (0%) 0/6 (0%) - -
Louwerens et al (2014) ND 0/20 (0%) - -
Martimbianco et al (2020) 4/4 (100%) 1/4 (25%) - -
Miller et al (2017) ND 13/16 (81%)
Mohamadi et al (2017) ND 4/14 (29%) - -
Sussmilch-Leitch et al (2012) 4/23 (17%) - 11/23 (48%)*** 15/23 (65%)***
(Continues)
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4 |  DISCUSSION
We have demonstrated several problems relating to the use 
of RoB assessment in SRs of tendinopathy management that 
need the attention of the research community. In our scoping 
review, we found that almost half of the included SRs did not 
use their RoB assessment in data synthesis. Additionally, only 
6.5% of SRs assessed RoB on an outcome level and not a study 
level while only 30% of all SRs used their RoB assessment for 
evidence grading, which is the primary purpose of performing 
a RoB assessment. In light of the substantial subjectivity and 
lack of transparency and reproducibility that governs the con-
duct of SRs, we strongly recommend that future SR authors 
determine overall RoB for each study (on an outcome level) 
with the use of clear and reproducible pre-defined criteria.
Whether overall RoB should be determined or not for 
each RCT is a controversial question and this controversy is 
apparent in the tools themselves. Although the creators of 
the original Cochrane Collaboration tool4 advised against 
rating overall RoB for each study but determining overall 
RoB on a domain level instead, this was neither explained 
further with clear, reproducible instructions nor was it appli-
cable in practice for evidence grading. The revised Cochrane 
Collaboration tool (RoB 2)5 published last year includes in-
structions on determining overall RoB for each study; how-
ever, the creators highlight that this needs to be done on an 
outcome level. Finally, the PEDro scale,6,7 which its creators 
define as “a scale to measure the quality of reports of RCTs,” 
does not define specific criteria or score cutoffs and is often 
incorrectly labeled as a “quality assessment” and not “RoB” 
tool. In addition to internal validity (RoB), measures of study 
quality include external validity (generalizability) and preci-
sion (freedom from random error), which the 10-item scale 
does not include. This is also acknowledged by the creators 
themselves.7
The comparison of the likelihood of each one of the three 
tools rating an RCT as “high overall risk” demonstrated clearly 
that the PEDro was overly generous as used by the SR authors, 
rating the majority of assessed RCTs (81.7%) as “low overall 
RoB”/”good overall quality.” The possibility of that substantial 
proportion of tendinopathy RCTs actually being of “low over-
all RoB” is not even entertained; many of them are not dou-
ble-blinded (due to their nature) and besides, the other two RoB 
assessment tools demonstrated greater proportions of “high 
overall RoB” RCTs. Finally, inter-tool reliability among the 
three tools was generally poor except for the comparison of the 
Cochrane Collaboration tool and the PEDro ≥ 8, which rein-
forces the need for PEDro to be used with stricter criteria.
When we assessed our own pre-defined criteria against 
those used by the SR authors, it was apparent that especially 
for the Cochrane Collaboration tool there were substan-
tial discrepancies. One might argue that our strict criteria 
resulted in a very low threshold of rating an RCT as “high 
overall RoB”; however, the recently published RoB 2 is very 
close to our criteria in that respect as all it takes for a “high 
overall RoB” is high RoB in a single domain. These marked 
disparities reflect the significant effects that subjectivity, in-
consistency, and lack of reproducibility can have on the re-
sults of the same SRs with regard to grading the quality of 
evidence. If we demonstrated inconsistencies this significant 
only by using different criteria for RoB assessment results as 
reported by the SR authors, one can imagine how much more 
substantial these disparities can be when the same RCTs are 
assessed by different people, with different tools, using dif-
ferent criteria for each tool. Finally, a naturally arising ques-
tion is therefore “how much bias is enough to distort the true 
Tool SR
SR authors' “high 
overall RoB”
DC “high overall 
RoB” Cochrane 
Collaboration DC “high overall RoB” PEDro
Tsikopoulos et al (2016) ND 4/5 (80%) - -
Toliopoulos et al (2014) ND 7/15 (47%) - -
Xiong et al (2019) ND 0/4 (0%) - -
Yan et al (2019) ND 0/5 (0%) - -
Zhang et al (2019) ND 0/8 (0%)
Mean Proportion 34.6% 55% - -
RoB 2 Murphy et al (2019) 2/7 (29%) NP** - -
Van der Vlist et al (2020) 21/28 (75%) NP** - -
Mean Proportion 52% - - -
Abbreviations: NA, not available; ND, not determined; SR, systematic review; RoB, risk of bias.
*Systematic review authors and author of present review (DC) used same criteria. 
**Not performed as tool includes instructions on determination of overall risk of bias. 
***Systematic review authors presented results of modified PEDro scale but assessed overall risk of bias based on Cochrane Collaboration tool. 
T A B L E  2  (Continued)
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result of an RCT?”; unfortunately, this and other similarly 
subjective judgments are needed for the conduct and report-
ing of all SRs.
The ideal RoB assessment tool does not exist. Subjectivity 
can never be removed completely from RoB assessment; how-
ever, this needs to be kept to a minimum and be complemented 
by transparency and reproducibility. These are exactly the 
aims of the revised Cochrane Collaboration tool, the creators 
of which state that they expect the new tool to be more likely 
to rate studies as “low overall RoB.”5 This was clearly not the 
case with the example SR used in the present review by van 
der Vlist et al8 who rated none of the 29 RCTs as “low risk.” 
Reasons for that might be either the actual presence of bias in 
all the included RCTs, strict thresholds used by the SR authors 
or poor performance of the tool itself. The same tool applied 
in the other SR46 included in this review identified a much 
higher proportion of “low overall RoB” RCTs (4/7). Despite 
attempts of the creators to make the tool more user friendly 
and reproducible,4 there is still significant subjectivity in some 
of its signaling questions (eg, “could assessment have been in-
fluenced by knowledge of intervention?” or “likely that miss-
ingness depended on true value”). However, importantly the 
T A B L E  3 A  Our risk of bias assessment of the 29 RCTs included in the systematic review by van der Vlist (2020)7 using the Cochrane 
Collaboration tool
First Author (y)
Internal Validity
(Cochrane's Collaboration Tool for Assessing Risk of Bias)
Overall 
RoB
Selection
bias
Performance
bias
Detection
bias
Attrition
bias
Reporting
bias
Other
Random 
sequence 
generation
Allocation 
concealment
Blinding of 
patients and 
staff
Blinding 
of outcome 
measures
Completeness 
of outcome 
data
Selective 
reporting
Balius et al (2016) Low ? High High Low Low Low High
Bell et al (2013) Low Low Low Low Low Low Low Low
Beyer et al (2015) Low ? High High ? Low ? High
Boesen et al (2017) Low Low Low Low Low Low Low Low
De Jonge et al (2010) ? Low High High High Low Low High
De Jonge et al (2011) Low Low Low Low Low Low Low Low
Ebbesen et al (2017) ? Low Low Low Low Low High Low
Heinemeier et al (2017) Low Low Low Low ? Low ? Low
Herrington & McCulloch (2007) High ? High High Low Low Low High
Hutchison et al (2013) Low Low Low Low Low Low Low Low
Krogh et al (2016) Low Low Low High Low Low Low High
Lynen et al (2017) Low Low High High Low Low Low High
Morrison et al (2017) Low Low Low High Low Low Low High
Munteanu et al (2015) Low Low Low Low Low Low Low Low
Njawaya et al (2018) Low Low High High Low High High High
Pearson et al (2012) Low ? High High High High High High
Rompe et al (2008) Low Low High High Low Low Low High
Rompe et al (2009) Low Low High High Low Low High High
Rompe et al (2009) Low Low High High Low Low Low High
Roos et al (2004) Low ? High High High Low High High
Silbernagel et al (2001) ? ? High High High High High High
Silbernagel et al (2007) Low Low High High ? High Low High
Stevens & Tan (2014) ? Low High High High Low Low High
Tumilty et al (2016) Low Low Low Low High Low Low Low
Tumilty et al (2012) Low Low Low Low Low Low Low Low
Usuelli et al (2018) ? Low High High Low High Low High
Yelland et al (2009) Low ? High High Low Low High High
Zhang et al (2013) Low Low High High Low Low Low High
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tool includes clear instructions on determining both RoB for 
each individual domain and overall RoB for each study and 
this is why we advocate its use by all future SR authors.
4.1 | Recommendations
In order to minimize inconsistency in RoB assessment and 
its use in data synthesis, we suggest the consistent use of 
RoB assessment across all journals publishing SRs. This 
will be achieved through the use of a single RoB assess-
ment tool that can be incorporated in the “Instructions for 
authors” section of each journal's website or even in the 
PRISMA statement57 and other SR guidance documents. 
Additionally, for subjectivity and lack of transparency to 
be kept to a minimum, RCT authors could include a RoB 
assessment of their own study (with justifications) that will 
remove the need for authors' judgments at an SR level. 
Similarly, this could be achieved by the consistent use of the 
same tool across publishing journals and its introduction in 
RCT guidance documents (eg, CONSORT).58 Finally, jour-
nals and reviewers should apply more stringent criteria for 
accepting low-quality RCTs and SRs with inadequate trans-
parency and reproducibility.
5 |  CONCLUSION
In the present review, we demonstrate several issues regard-
ing the use of RoB assessment in tendinopathy SRs both re-
lating to the tools themselves and their use by authors. Most 
importantly, there appears to be a lack of understanding on 
T A B L E  3 B  Our risk of bias assessment of the 29 RCTs included in the systematic review by van der Vlist (2020)7 using the PEDro Tool
Study 1 2 3 4 5 6 7 8 9 10
Total 
Score
Overall ≥ 
 6
Overall ≥ 
 8
Balius et al (2016) Yes No Yes No No No Yes Yes Yes Yes 6 Low High
Bell et al (2013) Yes Yes Yes Yes No Yes Yes Yes Yes Yes 9 Low Low
Beyer et al (2015) Yes No Yes No No No No No Yes Yes 4 High High
Boesen et al (2017) Yes Yes Yes Yes No Yes Yes Yes Yes Yes 9 Low Low
De Jonge et al (2010) Yes Yes Yes No No No No Yes Yes No 5  High High
De Jonge et al (2011) Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10 Low Low
Ebbesen et al (2017) No Yes Yes Yes No Yes Yes Yes No Yes 7 Low High
Heinemeier et al (2017) Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10 Low Low
Herrington & McCulloch 
(2007)
No No Yes No No No Yes Yes Yes No 4 High High
Hutchison et al (2013) Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes  10 Low Low
Krogh et al (2016) Yes Yes Yes Yes No No Yes Yes Yes Yes 8 Low Low
Lynen et al (2017) Yes Yes Yes No No No Yes Yes Yes Yes 7 Low High
Morrison et al (2017) Yes Yes Yes Yes No No Yes Yes Yes Yes 8 Low Low
Munteanu et al (2015) Yes Yes Yes Yes No Yes Yes Yes Yes Yes 9 Low Low
Njawaya et al (2018) Yes Yes Yes No No No Yes Yes Yes No 6 Low High
Pearson et al (2012) Yes No Yes No No No No Yes No No 3 High High
Rompe et al (2008) Yes Yes Yes No No No Yes Yes Yes Yes 7  Low High
Rompe et al (2009) Yes Yes Yes No No No Yes Yes Yes Yes 7 Low High
Rompe et al (2007) Yes Yes Yes No No No Yes Yes Yes Yes 7 Low High
Roos et al (2004) Yes No No No No No No Yes Yes Yes 4 High High
Silbernagel et al (2001) Yes No No No No No No Yes No Yes 3 High High
Silbernagel et al (2007) Yes Yes Yes No No No No Yes No Yes 5 High High
Stevens & Tan (2014) No Yes Yes No No No No Yes Yes Yes 5 High High
Tumilty et al (2016) Yes Yes Yes Yes No Yes No Yes Yes Yes 8 Low Low
Tumilty et al (2012) Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10 Low Low
Usuelli et al (2018) No Yes Yes No No No Yes Yes Yes No 5 High High
Yelland et al (2009) Yes Yes No No No No Yes Yes Yes Yes 6 Low High
Zhang et al (2013) Yes Yes Yes No No No Yes Yes Yes Yes 7 Low High
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the appropriate use of RoB assessment and its incorpora-
tion in data syntheses. We recommend the consistent use 
of a single RoB assessment tool across all publishing jour-
nals and guidance documents and the application of more 
stringent criteria when both RCTs and SRs are assessed for 
publication.
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